CollPlant Biotechnologies (NASDAQ:CLGN) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Earnings & Valuation
This table compares CollPlant Biotechnologies and Surgalign's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| CollPlant Biotechnologies | $2.32 million | 35.32 | $-11,160,000.00 | ($1.29) | -11.20 |
| Surgalign | $308.38 million | 0.68 | $-211,640,000.00 | ($0.16) | -11.81 |
CollPlant Biotechnologies has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
15.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 53.5% of Surgalign shares are held by institutional investors. 3.7% of Surgalign shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares CollPlant Biotechnologies and Surgalign's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| CollPlant Biotechnologies | -149.91% | -116.41% | -59.02% |
| Surgalign | -56.07% | -101.34% | -18.44% |
Volatility & Risk
CollPlant Biotechnologies has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for CollPlant Biotechnologies and Surgalign, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| CollPlant Biotechnologies | 0 | 0 | 1 | 0 | 3.00 |
| Surgalign | 0 | 0 | 4 | 0 | 3.00 |
CollPlant Biotechnologies presently has a consensus target price of $26.00, suggesting a potential upside of 79.93%. Surgalign has a consensus target price of $4.3333, suggesting a potential upside of 129.28%. Given Surgalign's higher probable upside, analysts plainly believe Surgalign is more favorable than CollPlant Biotechnologies.
Summary
Surgalign beats CollPlant Biotechnologies on 11 of the 13 factors compared between the two stocks.
